Canyon Hopkins, PharmD

Sacituzumab govitecan-hziy (Trodelvy) is indicated for the treatment of patients with triple-negative breast cancer who have received 2 prior therapies at minimum for metastatic disease.

Enfortumab vedotin-ejfv (Seagen; Padcev) is a first-in-class antibody-drug conjugate approved for patients with previously treated locally advanced or metastatic urothelial cancer.